Can Janus kinase inhibition improve ocular graft versus host disease?
作者信息
Sajjan Seema, Tibbs Ellis, Utz Megan, Rapoport Aaron P, Yared Jean, Dahiya Saurabh, Cao Xuefang, Hardy Nancy, Sunshine Sarah B
机构信息
Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
出版信息
Ocul Surf. 2023 Apr;28:27-29. doi: 10.1016/j.jtos.2023.01.001. Epub 2023 Jan 10.
Abstract
摘要
相似文献
1
Can Janus kinase inhibition improve ocular graft versus host disease?抑制 Janus 激酶能否改善眼部移植物抗宿主病？
Ocul Surf. 2023 Apr;28:27-29. doi: 10.1016/j.jtos.2023.01.001. Epub 2023 Jan 10.
2
The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.Janus 激酶信号通路在移植物抗宿主病和移植物抗白血病中的作用
Biol Blood Marrow Transplant. 2018 Jun;24(6):1125-1134. doi: 10.1016/j.bbmt.2017.12.797. Epub 2017 Dec 28.
3
Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease.用于控制慢性移植物抗宿主病的新兴疗法。
Biol Blood Marrow Transplant. 2018 Jan;24(1):19-26. doi: 10.1016/j.bbmt.2017.10.006. Epub 2017 Oct 12.
4
Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects.Janus 激酶抑制治疗移植物抗宿主病：现状与展望。
Drugs. 2019 Sep;79(14):1499-1509. doi: 10.1007/s40265-019-01174-1.
5
Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.芦可替尼治疗儿童造血干细胞移植后激素耐药移植物抗宿主病：高缓解率和可管理的毒性。
Pediatr Hematol Oncol. 2021 May;38(4):331-345. doi: 10.1080/08880018.2020.1868637. Epub 2021 Mar 4.
6
Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice.移植临床实践中眼部慢性移植物抗宿主病诊断及疾病活动度的预测模型
Haematologica. 2015 Sep;100(9):1228-36. doi: 10.3324/haematol.2015.124131. Epub 2015 Jun 18.
7
Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.抗体药物偶联物加 JAK 抑制剂使 MHC 错配的同种异体造血干细胞移植成为可能。
J Clin Invest. 2021 Dec 15;131(24). doi: 10.1172/JCI145501.
8
ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.ANZTCT 共识立场声明：芦可替尼治疗激素难治性急性和慢性移植物抗宿主病。
Intern Med J. 2023 Dec;53(12):2319-2329. doi: 10.1111/imj.16255. Epub 2023 Nov 28.
9
How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.我们如何在异基因移植中管理针对骨髓纤维化的JAK抑制。
Eur J Haematol. 2015 Feb;94(2):115-9. doi: 10.1111/ejh.12455. Epub 2014 Nov 21.
10
A rapidly expanding cutaneous tumour in the context of a Janus kinase inhibitor agent following allogeneic stem cell transplant.异基因干细胞移植后使用 Janus 激酶抑制剂后迅速增大的皮肤肿瘤。
Clin Exp Dermatol. 2022 Nov;47(11):2059-2064. doi: 10.1111/ced.15305. Epub 2022 Aug 25.
引用本文的文献
1
Novel Tear Biomarkers in Ocular Graft Versus Host Disease Associated with Th1/Th2 Immune Responses: A Case Series and Literature Review.与Th1/Th2免疫反应相关的眼部移植物抗宿主病中的新型泪液生物标志物：病例系列及文献综述
Int J Mol Sci. 2025 May 1;26(9):4311. doi: 10.3390/ijms26094311.
2
Systemic Treatment with the Janus Kinase Inhibitor Baricitinib in Ocular Chronic Graft-versus-Host Disease.使用JAK激酶抑制剂巴瑞替尼进行全身治疗在眼部慢性移植物抗宿主病中的应用
Ophthalmol Sci. 2024 Sep 30;5(1):100627. doi: 10.1016/j.xops.2024.100627. eCollection 2025 Jan-Feb.
本文引用的文献
1
Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops ("Triple Play") in Recalcitrant Immunological Ocular Surface Diseases.免疫抑制、免疫调节和泪液替代滴眼剂联合治疗（三联疗法）在难治性免疫性眼表疾病中的应用。
Ocul Surf. 2022 Jan;23:1-11. doi: 10.1016/j.jtos.2021.11.002. Epub 2021 Nov 10.
2
Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.造血细胞移植后眼移植物抗宿主病：来自 CIBMTR 晚期效应和生活质量工作组以及 EBMT 移植并发症工作组的专家综述。
Bone Marrow Transplant. 2019 May;54(5):662-673. doi: 10.1038/s41409-018-0340-0. Epub 2018 Dec 7.
3
TFOS DEWS II pathophysiology report.TFOS DEWS II 病理生理学报告。
Ocul Surf. 2017 Jul;15(3):438-510. doi: 10.1016/j.jtos.2017.05.011. Epub 2017 Jul 20.
4
Mechanisms and consequences of Jak-STAT signaling in the immune system.Jak-STAT信号通路在免疫系统中的机制及后果
Nat Immunol. 2017 Mar 22;18(4):374-384. doi: 10.1038/ni.3691.
5
Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后眼部移植物抗宿主病的发病率及危险因素
Bone Marrow Transplant. 2015 Nov;50(11):1459-64. doi: 10.1038/bmt.2015.187. Epub 2015 Aug 24.
6
International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part I).国际慢性眼部移植物抗宿主病（GVHD）共识小组：慢性GVHD的拟诊标准（第一部分）
Sci Rep. 2013 Dec 5;3:3419. doi: 10.1038/srep03419.
Zotero 插件